JNCE Stock Gains 25% After Updated Collaboration with Celgene

JNCE stock

JNCE stock is moving up sharply following an update from Jounce Therapeutics (NASDAQ:JNCE) regarding its partnership with Celgene (NASDAQ:CELG).

Investors Cheer the News

Manufacturing of predictive biomarkers and immunotherapies is big business in the biotech space, and Jounce Therapeutics is one of the players in that thriving industry. However, yesterday, the company made a major announcement that sent JNCE stock on fire. The company announced a significant update with regards to its strategic collaboration with Celgene Corporation.

The collaboration had been in place since 2016, but late Tuesday, the company announced the provisions of ...

Read The Full Article On MicroSmallCap.com

Get early insight on hidden secret gems on MicroSmallCap. Follow Crypto, Mining, Cannabis and Energy stocks and get free research reports here.

All content provided by MicroSmallCap is subject to our Terms Of Use and Disclaimer.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.